

Mini Review

Similarities among Alzheimer's Disease, Parkinson's Disease and Dementia May Call for a Similar Treatment


Chakraborty A* and Diwan A

AllExcel, USA

Abstract

Alzheimer's Disease (AD), Parkinson's Disease (PD), and Dementia are all age-related neurodegenerative diseases. In the US, AD victims are increasing every year from 5.5 million in 2018 to 13.8 million by 2050. PD patient are calculated to increase from 7 K to 1 million by 2030. Results from accumulation of extracellular amyloid- β ($A\beta$) peptide and deposition of intracellular *tau* aggregated tangles. The prognosis of AD and PD both is the onset of Dementia, which causes memory impairment irreversibly, thinking capabilities, orientation, comprehension, learning any new things, and taking the judgment. Dementia is currently the seventh leading cause of death among all diseases worldwide. Here we will discuss the similarities in the disease nature and cause of AD, PD and Dementia at their cellular and molecular level to find a common therapy for them.

Keywords: Alzheimer's disease; Parkinson's disease; Dementia; Tangles; Plaques; Cognitive function



Abbreviations

AD: Alzheimer's disease; LOAD: Late-onset AD; SPs: Senile Plaques; NMDA: N-methyl-D-aspartate; $A\beta$: Amyloid-beta peptide; EphB2 receptors: Ephrin type-B receptor 2; NFTs: Neuro Fibrillary Tangles; ApoE: Apolipoprotein E; pTau: Hyperphosphorylated Tau; BACE1: β -site APP Cleaving Enzyme Type-I; APP: Amyloid Precursor Protein; LTD: Long-Term Depression; EOAD: Early-Onset AD; MTs: Microtubules; PSEN1 and PSEN2: Presenilins 1 and 2; ptau: Phosphorylated 'tau'; AICD: APP Intracellular Domain; Cdk-5: Cyclin-Dependent Kinase 5; sAPP β : Soluble Ectodomain- β ; cdc-2: Cell-cycle kinase; sAPP α : Soluble Ectodomain- α ; ROS: Reactive Oxygen Species

Citation: Chakraborty A, Diwan A. Similarities among Alzheimer's Disease, Parkinson's Disease and Dementia May Call for a Similar Treatment. *Neurol Curr Res.* 2022;2(2):1014.

Copyright: © 2022 Ashok Chakraborty

Publisher Name: Medtext Publications LLC

Manuscript compiled: May 11th, 2022

***Corresponding author:** Ashok Chakraborty, AllExcel Inc, CT, USA, E-mail: Ashok.chakraborty@allexcel.com

Introduction

The typical neurodegenerative diseases are Parkinson's disease (PD) and Alzheimer's disease (AD) and Dementia [1]. Both PD and AD display mitochondrial dysfunction and oxidative stress [2-4], while Dementia is a broad term that stands for an irreversible loss of thinking ability, memory, and other mental capabilities [5,6]. In fact, Dementia is considered as the end results of AD and PD. All these diseases are believed to be due to aging. This article will discuss the similarities and differences among these neural diseases and find for some appropriate treatment possibilities.

Conclusions

The greatest risk factor for AD, PD and Dementia is age. It appears that *tau* and $A\beta$ are the hallmarks for both AD and PD in the brain and eventually for Dementia [80,81]. This review indicates large similarities in genetic risk factors between diseases, AD, PD and Dementia. The genes that were discussed above have the possibility as potential biomarkers.

Using KEGG pathway analysis [82], Wang et al. [82,83] discovered that PD and AD were both dysfunctional in synaptic vesicle and mitochondrial oxidative metabolism pathways. The enriched genes in AD cases were greater than PD. Although PD and AD have common characteristics [84]; cognition and patients with learning or memory damage in AD was more severe than in PD [85].

Epigenetic regulatory mechanisms, such as chromatin remodeling, DNA methylation, histone variant and histone post-translational modification have been suggested to regulate numerous aspects of axonal development and neuronal survival [86]. One study presented evidence that changes in H3K27ac or H3K4me3 occurred in connection with genetic variants in AD. This is an important function for immune-associated enhancers and promoter proteins in determining AD susceptibility [87]. Another study demonstrated that H4K16ac, a histone associated with DNA repair and neurodegenerative disorders, is significantly reduced in the cortex of AD patients. This suggests that the aged brains of these individuals are incapable of up-regulating H4K16ac [88]. In addition, multiple reports have associated loss of H3K4me3, a protein related to gene activation, with the deterioration found in PD. Over expression

Table 1: Basic information of the diseases.

	AD	PD	Dementia
Affected Region/ Cause:	<ul style="list-style-type: none"> Extensive neuronal loss that leads to brain tissue atrophy. Neurofibrillary tangles in the neocortex and hippocampus [7] Extracellular amyloid- Aβ deposits, senile plaques and amyloid plaques [8]. 	<ul style="list-style-type: none"> Neuron degeneration and loss of dopamine in the substantia nigra pars compacta in the midbrain [9,10]. 	Like AD and PD, Dementia is also an aging issue, but loss of neural cells due to some neurotoxic agents, external brain injury is also prevalent.
Symptoms:	<ul style="list-style-type: none"> Progressive memory loss. Affects cognitive functions such as communication and movement [11]. 	<ul style="list-style-type: none"> The clinical manifestations of PD are bradykinesia, resting tremor and postural instability [11]. 	<ul style="list-style-type: none"> Getting lost Trouble with complex but familiar tasks, like fixing a meal or paying bills Personality changes, like depression, agitation, paranoia, and mood swing
Age of Onset:	<ul style="list-style-type: none"> Late-onset variety-symptoms first appear in mid-60s. Early-onset AD begin between a person's 30s and mid-60s [12]. 	<ul style="list-style-type: none"> The average age of Parkinson's disease is 56. Around 4 percent of Parkinson's patients are diagnosed before the age of 50. The youngest recorded case of Parkinson's was a 12-year-old patient [13]. 	<ul style="list-style-type: none"> Dementia is commonly found in people over the age of 65. However, it can affect people in their 30s, 40s, or 50s [14].
Prognosis:	<ul style="list-style-type: none"> Prognosis Dementia (Irreversible loss memory) [12] 	<ul style="list-style-type: none"> Prognosis Dementia (Irreversible loss memory) [13] 	<ul style="list-style-type: none"> Dementia is a severe disease with a poor prognosis. Mortality risks are estimated to be at least two times higher than mortality risks in non-demented patients [15] It is expected that Dementia will be among the leading causes of death in the near future instead of Cardiovascular Diseases (CVDs) [16,17].

Table 2: Molecular basis of the diseases.

AD	PD	Dementia
<ul style="list-style-type: none"> Mutations of the β-amyloid (Aβ) precursor protein on chromosome 21, cause Alzheimer disease (AD) [18]. Lewy bodies are a marker protein aggregation in PD, are also frequently observed in cases of classic AD, including in patients with mutations in APP, PSEN1, and PSEN2 [19,20]. 	The main neuropathologic hallmark of PD is the accumulation of α -synuclein in neurons in the form of Lewy bodies [21].	<ul style="list-style-type: none"> Lewy Body Dementia (LBD) is a common type of degenerative Dementia in elderly people [22]. Many patients with LBD have AD pathology because they have Lewy bodies, cortical amyloid plaques and neurofibrillary tangles in common [22].
In transgenic mice, the accumulation of α -synuclein could significantly disrupt cognition [23].		
It is generally believed that oxidative stress and mitochondrial dysfunction are likely to be the common mechanisms in PD, AD and Dementia [24].		
<ul style="list-style-type: none"> Linkage analysis showed that the better part of AD signal on chromosome 12q13 near 50 Mb was actually caused by a subset of families fulfilling neuropathological criteria for LBD (i.e., 8 of 54 families) [25-27]. 	<ul style="list-style-type: none"> Abundance of 4-repeat <i>tau</i> has also been frequently associated with PD. This possibly suggests a common <i>tau</i>-related pathogenic mechanism shared by FTD and late-onset PD [28]. 	
<ul style="list-style-type: none"> Mutations in microtubule-associated protein <i>tau</i>. 	<ul style="list-style-type: none"> Mutations in at least 5 genes has been shown to cause familial early-onset Parkinsonisms: <ul style="list-style-type: none"> --(α-synuclein [SNCA or PARK1] [32]; --parkin [PRKN or PARK2] [33] --DJ-1 [DJ1 or PARK7] [34] --PTEN-induced putative kinase 1 [PINK1 or PARK6] [35]; --leucine-rich repeatkinase 2 [LRRK2 or PARK8] [36,37]. 	<ul style="list-style-type: none"> Rare missense mutations in MAPT leads to a syndrome of Fronto-Temporal Dementia (FTD) with parkinsonism linked to chromosome 17 [FTDP-17] [25].
<ul style="list-style-type: none"> Fully penetrant autosomal dominant mutations in 3 genes (i.e. APP, PSEN1, and PSEN2) have been shown to cause AD [29-31]. 		

of H3K4me3 can accelerate A-T mutation that mitigates behavioral impairments and neurodegeneration [89-91].

HDAC inhibitors can prevent neuro-degeneration in models of AD [92-95]. This paper demonstrate that epigenetic profiles are regulated

in neurodegenerative diseases and gives a better understanding of these mechanisms that can provide the foundation for developing more precisely targeted epigenome therapies. For example, recent work suggesting that epigenetic editing can improve cognition in AD

Table 3: Cellular basis of the diseases.

AD	PD	Dementia
<ul style="list-style-type: none"> Both <i>sirtuin</i> and <i>REST</i> signaling pathways are disturbed both the diseases, AD, PD [38]. 		<ul style="list-style-type: none"> Affected neurons display intracellular <i>tau</i>-positive inclusions that are distinct from the neurofibrillary tangles observed in AD [40].
<ul style="list-style-type: none"> Lewy bodies, protein aggregation and <i>α-synuclein</i> in PD are also found in >60% of AD cases [39]. 		<ul style="list-style-type: none"> The first FTD mutations was identified in cases accompanied by parkinsonism and showing genetic linkage to chromosome 17q21, near the <i>tau</i> gene (FTDP-17) [25]
<ul style="list-style-type: none"> AD cases have <i>tau</i> tangles. 	<ul style="list-style-type: none"> <i>tau</i> aggregation is shown in ~50% of PD cases snRNP70 may co-localize in PD cases [41]. 	<ul style="list-style-type: none"> Subsequently, disease-causing mutations were identified in <i>tau</i> (gene: MAPT) [22].

Table 4: Genes involved.

AD	PD	Dementia
<ul style="list-style-type: none"> The strong risk factor for AD, ApoE4, has been related to cognitive decline in PD [43] and Dementia also [44-46]. Genetic overlap between AD, PD and Dementia was also discovered [47,48]. Genetic association study proved rs76904798 of LRRK2 significantly reduce late-onset AD risk in Han Chinese [48]; and it is found Dominant in dementia [36,37]. 		
<ul style="list-style-type: none"> APP: Ab Precursor Protein, Dominant [49]. 		<ul style="list-style-type: none"> PRKN: Parkin: Recessive [33]
<ul style="list-style-type: none"> PSEN1: Presenilin1; Dominant [29] 		<ul style="list-style-type: none"> Recent reports have suggested that some cases of PD and FTD may also be caused by mutations in PSEN1 [50]
<ul style="list-style-type: none"> PSEN2: Presenilin 2: Dominant [30,31]. 		<ul style="list-style-type: none"> PINK1: PTEN induced putative kinase 1: Recessive [35].
<ul style="list-style-type: none"> The rs356182 locates in the intron of SNCA, which is the coding gene of <i>α-synuclein</i> which has key role PD genesis [51-53]. 		<ul style="list-style-type: none"> SNCA: <i>α-synuclein</i>: Dominant [32].
<ul style="list-style-type: none"> MAPT: Microtubule-associated protein tau: Dominant [22]. 		<ul style="list-style-type: none"> DJ1: DJ1: Recessive [34].
<ul style="list-style-type: none"> The AD risk factor SORL1 had been identified to be associated with PD recently [54]. 		

Table 5: Epigenetics of the diseases.

AD	PD	Dementia
<ul style="list-style-type: none"> Single nucleotide polymorphism (SNP) analysis of PD and AD revealed that 12 of them, such as <i>EPB41L5</i>, <i>CYP26B1</i>, <i>IQCB1</i>, <i>DCPIA</i>, <i>CLGN</i>, <i>TDRD6</i>, <i>PSORS1C1</i>, <i>PARP12</i>, <i>WISPI</i>, <i>PIK3C2A</i>, <i>CLMN</i>, <i>DHX33</i>, are common in them [38]. 		
<ul style="list-style-type: none"> <i>SNRNP70</i> encodes the small nuclear ribonucleoprotein snRNP70 co-localizes with <i>tau</i> in AD [55]. 		<ul style="list-style-type: none"> The hub gene <i>SNRNP70</i> has been shown to be differentially expressed in PD blood and Dementia [56].

Table 6: Possibilities of gene therapy.

AD	PD	Dementia
Gene therapy can be used to treat diseases by the introduction of therapeutic genes, by replacing, silencing, or correcting faulty genes.		
<ul style="list-style-type: none"> APOE is the genetic risk factor. Significantly increases the incidence of Late-Onset AD (LOAD) [57,58]. ECE can participate in Aβ degradation and could be a potential target for a pharmacological or gene therapeutic approach [59,60]. Lentivirus mediated gene delivery of cathepsin B reduced anti-Aβ antibody, and Thioflavin S-positive amyloid plaques, supporting a role for cathepsin B in Aβ degradation [65]. Gene delivery of IDE could possibly enhance Aβ degradation and influence AD pathology [66,67]. Down-regulation of AD-associated proteins, BAC1, APP, by siRNA [68,69]. 	<ul style="list-style-type: none"> Genome editing of mutations in several genes associated with both familial- and sporadic PD, including parkin, LRRK2, SNCA, PINK1, DJ-1, VPS35, DNAJC13, CHCHD2 [61]. Gene therapy with growth factors and also some non-disease modifying targets, such as TH, GCH and AADC and VMAT2 could be relevant treatment for patients [62]. 	<ul style="list-style-type: none"> Approximately 30% of patients with FTD show a clear autosomal dominant inheritance pattern, where one copy of a mutated gene causes the genetic condition. The three genes commonly involved in hereditary of FTD are <i>granulin (GRN)</i>, <i>C9orf72</i> and <i>MAPT</i> [63,64]. AAV gene therapy is a potential avenue for disease modification in GRN carriers [70,71].

highlights the potential of epigenetic regulation-based gene therapy for neurodegenerative disorders [96].

Gene modification of stem cells prior to transplantation can be useful for increasing cell survival and making them more effective [97]. Due to the loss of cholinergic neurotransmitters in AD, gene-modified cells transplantation can produce acetylcholine (ACh) and could be beneficial to the patients. Primary fibroblast cell line genetically engineered to express choline acetyl transferase showed the

capacity to produce ACh after transplantation into the hippocampus of rats [98]. Another example of the use of the facilitation of gene therapy for AD is the over expression of Nephrilysin (NEP), an Aβ degrading protease that has been shown to ameliorate extracellular amyloids [99].

Transgenic mice (APP/PS1) injected with lentiviral vector expressing NEP showed a reduction in Ab deposits [100], and MSCs over expressing the NEP gene demonstrated the ability to degrade

Table 7: Possibilities of cell therapy.

AD	PD	Dementia
Cure may be possible if right cell can be transplanted which can grow, produce dopamine, can survive for longer period of times, but can differentiate, and should not have any ethical issues.		
<ul style="list-style-type: none"> • Neural stem cells (hNSCs): Stem cells have high migratory capacity after transplantation into the brain, and can be genetically modified <i>in vitro</i>. Therefore, they can be an efficient candidate to deliver neurotropic factors or enhance gene expression to modify the course of the disease [72-74]. • They also release DA in response to substrate (DOPA) - induced condition than those obtained in control groups [75]. • These cells also express DAT (Dopamine Transporter) that controls the physiological label of DA in the synaptic cleft [75]. 		
ESCs-derived NPCs: Transplantation of these cells into the injured hippocampus demonstrate the formation of synapses between host and grafted neural cells, and also improve the memory dysfunction [76,77].		
Induced Pluripotent Stem Cells (iPSCs): Neurons derived from human iPSCs are endowed with a remarkable potential to establish orthotropic long-range projections in the adult mammalian brain [78].		
NSCs: In mouse AD model, the transplantation of NSCs was reported to improved cognition function mediated by the neurotropic factor BDNF [79].		

A β peptides *in vitro* [101]. Similar results were obtained *in vivo* with transgenic mice that were transplanted with fibroblasts engineered with lentivirus carrying NEP [102].

Recently we have created modified neural stem cells which can differentiate, produce dopamine, BDNF/GDNF [103-105]. Our notion, therefore, is that the cell-replacement therapy of AD/PD/Dementia patients with a modified neural cells could be relevant [106-107] (Tables 1-7).

Acknowledgments

We acknowledge all our colleagues for their help during the preparation of the manuscript by providing all the relevant information. Thanks to Ms. Bethany Pond for her Editorial assistants.

Funding

This research received no specific grant from any funding agency in the public, commercial, or not-for-profit sectors.

Authors' Contribution

Both the authors have contributed equally to preparing this article, reading, and approving the final manuscript.

Conflict of Interests

The authors declare no conflict of interests.

Consent for Publications

Both the authors have agreed to submit this paper for publication.

References

- Nussbaum RL, Ellis CE. Alzheimer's disease and Parkinson's disease. *N Engl J Med*. 2003;348(14):1356-64.
- Lin MT, Beal MF. Mitochondrial dysfunction and oxidative stress in neurodegenerative diseases. *Nature*. 2006;443(7113):787-95.
- Khan TA, Hassan I, Ahmad A, Perveen A, Aman S, Quddusi S, et al. Recent updates on the dynamic association between oxidative stress and neurodegenerative disorders. *CNS Neurol Disord Drug Targets*. 2016;15(3):310-20.
- Denzer I, Munch G, Friedland K. Modulation of mitochondrial dysfunction in neurodegenerative diseases via activation of nuclear factor erythroid-2-related factor 2 by food-derived compounds. *Pharmacol Res*. 2016;103:80-94.
- Mayeux R, Chen J, Mirabello E, Marder K, Bell K, Dooneief G, et al. An estimate of the incidence of dementia in idiopathic Parkinson's disease. *Neurology*. 1990;40(10):1513-7.
- Ebmeier KP, Calder SA, Crawford JR, Stewart L, Cochrane RHB, Besson JAO. Dementia in idiopathic Parkinson's disease: prevalence and relationship with symptoms and signs of Parkinsonism. *Psychological Medicine*. 1991;21(1):69-76.
- Dickson DW. Neuropathological diagnosis of Alzheimer's disease: A perspective from longitudinal clinicopathological studies. *Neurobiol Aging*. 1997;18(4 Suppl):S21-6.
- Hardy J, Selkoe DJ. The amyloid hypothesis of Alzheimer's disease: Progress and problems on the road to therapeutics. *Science*. 2002;297(5580):353-6.
- German DC, Manaye K, Smith WK, Woodward DJ, Saper CB. Midbrain dopaminergic cell loss in Parkinson's disease: Computer visualization. *Ann Neurol*. 1989;26(4):507-14.
- Obeso JA, Rodriguez-Oroz MC, Goetz CG, Marin C, Kordower JH, Rodriguez M, et al. Missing pieces in the Parkinson's disease puzzle. *Nat Med*. 2010;16(6):653-61.
- Jankovic J. Parkinson's disease: Clinical features and diagnosis. *J Neurol Neurosurg Psychiatry*. 2008;79(4):368-76.
- NIA. Alzheimer's disease Fact Sheet.
- Parkinson's. 11 Facts about Parkinson's disease you May Not Know.
- Healthline. 11 Early Signs of Dementia.
- Dewey ME, Saz P. Dementia, cognitive impairment and mortality in persons aged 65 and over living in the community: a systematic review of the literature. *Int J Geriatr Psychiatry*. 2001;16(8):751-61.
- James BD, Leurgans SE, Hebert LE, Scherr PA, Yaffe K, Bennett DA. Contribution of Alzheimer disease to mortality in the United States. *Neurology*. 2014;82(12):1045-50.
- Weuve J, Hebert LE, Scherr PA, Evans DA. Deaths in the united states among persons with Alzheimer's disease (2010–2050). *Alzheimers Dement*. 2014;10(12):e40-6.
- Harlin MCC, Mullan M, Brown J, Crawford E, Fidani L, Giuffra L, et al. Segregation of a missense mutation in the amyloid precursor protein gene with familial Alzheimer's disease. *Nature*. 1991;349(6311): 704-6.
- Hamilton RL. Lewy bodies in Alzheimer's disease: a neuropathological review of 145 cases using alpha-synuclein immunohistochemistry. *Brain Pathol*. 2000;10(3):378-84.
- Clinton LK, Blurton-Jones M, Myczek K, Trojanowski JQ, LaFerla FM. Synergistic interactions between Abeta, tau, and alpha-synuclein: acceleration of neuropathology and cognitive decline. *J Neurosci*. 2010;30(21):7281-9.
- Kalinderi K, Bostantjopoulou S, Fidani L. The genetic background of Parkinson's disease: current progress and future prospects. *Acta Neurol Scand*. 2016;134(5):314-26.
- McKeith IG, Galasko D, Kosaka K, Perry EK, Dickson DW, Hansen LA, et al. Consensus guidelines for the clinical and pathologic diagnosis of dementia with Lewy bodies (DLB): report of the consortium on DLB international workshop. *Neurology*. 1996;47(5):1113-24.
- Clinton LK, Blurton-Jones M, Myczek K, Trojanowski JQ, LaFerla FM. Synergistic interactions between Abeta, tau, and alpha-synuclein: acceleration of neuropathology and cognitive decline. *J Neurosci*. 2010;30(21):7281-9.
- Zawia NH, Lahiri DK, Cardozo-Pelaez F. Epigenetics, oxidative stress, and Alzheimer disease. *Free Radic Biol Med*. 2009;46(9):1241-9.
- Bertram L, Tanzi RE. The genetic epidemiology of neurodegenerative disease. *J Clin Invest*. 2005;115(6):1449-57.
- Kehoe P, De Vrieze FW, Crook R, Wu WS, Holmans P, Fenton I, et al. A full genome scan for late onset Alzheimer's disease. *Hum Mol Genet*. 1999;8(2):237-45.

27. Curtis D, North BV, Sham PC. A novel method of two-locus linkage analysis applied to a genome scan for late onset Alzheimer's disease. *Ann Hum Genet.* 2001;65(Pt 5):473-81.
28. Healy DG, Abou-Sleiman PM, Lees AJ, Casas JP, Quinn N, Bhatia K, et al. Tau gene and Parkinson's disease: a case-control study and meta-analysis. *J Neurol Neurosurg Psychiatr.* 2004;75(7):962-5.
29. Sherrington R, Rogaev EI, Liang Y, Rogaeva EA, Levesque G, Ikeda M, et al. Cloning of a gene bearing missense mutations in early-onset familial Alzheimer's disease. *Nature.* 1995;375(6534):754-60.
30. Rogaev EI, Sherrington R, Rogaeva EA, Levesque G, Ikeda M, Liang Y, et al. Familial Alzheimer's disease in kindreds with missense mutations in a gene on chromosome 1 related to the Alzheimer's disease type 3 gene. *Nature.* 1995;376(6543):775-8.
31. Levy-Lahad E, Wasco W, Poorkaj P, Romano D, Oshima J, Pettingell W, et al. Candidate gene for the chromosome 1 familial Alzheimer's disease locus. *Science.* 1995;269(5226):973-7.
32. Polymeropoulos MH, Lavedan C, Leroy E, Ide SE, Dehejia A, Dutra A, et al. Mutation in the alpha-synuclein gene identified in families with Parkinson's disease. *Science.* 1997;276(5321):2045-7.
33. Kitada T, Asakawa S, Hattori N, Matsumine H, Yamamura Y, Minoshima S, et al. Mutations in the parkin gene cause autosomal recessive juvenile parkinsonism. *Nature.* 1998;392(6676):605-8.
34. Bonifati V, Rizzu P, van Baren MJ, Schaap O, Breedveld GJ, Krieger E, et al. Mutations in the DJ-1 gene associated with autosomal recessive early-onset parkinsonism. *Science.* 2003;299(5604):256-9.
35. Valente EM, Abou-Sleiman PM, Caputo V, Muqit MMK, Harvey K, Gispert S, et al. Hereditary early-onset Parkinson's disease caused by mutations in PINK1. *Science.* 2004;304(5674):1158-60.
36. Zimprich A, Biskup S, Leitner P, Lichtner P, Farrer M, Lincoln S, et al. Mutations in LRRK2 cause autosomal-dominant parkinsonism with pleomorphic pathology. *Neuron.* 2004;44(4):601-7.
37. Paisan-Ruiz C, Jain S, Evans EW, Gilks WP, Simón J, van der Brug M, et al. Cloning of the gene containing mutations that cause PARK8-linked Parkinson's disease. *Neuron.* 2004;44(4):595-600.
38. Kelly J, Moyeed R, Carroll C, Albani D, Li X. Gene expression meta-analysis of Parkinson's disease and its relationship with Alzheimer's disease. *Mol Brain.* 2019;12:16.
39. Kaźmierczak A, Czapski GA, Adamczyk A, Gajkowska B, Strosznajder JB. A novel mechanism of non-A β component of Alzheimer's disease amyloid (NAC) neurotoxicity. Interplay between p53 protein and cyclin-dependent kinase 5 (Cdk5). *Neurochem Int.* 2011;58(2):206-14.
40. Zhang X, Gao F, Wang D, Li C, Fu Y, He W, Zhang J. Tau pathology in Parkinson's disease. *Front Neurol.* 2018;9:809.
41. Brun A. Frontal lobe degeneration of non-Alzheimer type I. *Neuropathology. Arch Gerontol Geriatr.* 1987;6(3):193-208.
42. Hutton M, Lendon CL, Rizzu P, Baker M, Froelich S, Houlden HH, et al. Association of missense and 5'-splice-site mutations in tau with the inherited dementia FTDP-17. *Nature.* 1998;393:702-5.
43. Kwon OD. Is There Any Relationship between Apolipoprotein E Polymorphism and Idiopathic Parkinson's Disease? *J Alzheimers Dis Parkinsonism.* 2017;7(1):292.
44. Verpillat P, Camuzat A, Hannequin D, Thomas-Anterion C, Puel M, Belliard S, et al. Apolipoprotein E gene in frontotemporal dementia: an association study and meta-analysis. *Eur J Hum Genet.* 2002;10(7):399-405.
45. Strittmatter WJ, Saunders AM, Schmechel D, Pericak-Vance M, Enghild J, Salvesen GS, et al. Apolipoprotein E: high-avidity binding to beta-amyloid and increased frequency of type 4 allele in late-onset familial Alzheimer disease. *Proc Natl Acad Sci U S A.* 1993;90(5):1977-81.
46. Schmechel DE, Saunders AM, Strittmatter WJ, Crain BJ, Hulette CM, Joo SH, et al. Increased amyloid beta-peptide deposition in cerebral cortex as a consequence of apolipoprotein E genotype in late-onset Alzheimer disease. *Proc Natl Acad Sci U S A.* 1993;90(20):9649-53.
47. Belin AC, Bjork BF, Westerlund M, Galter D, Sydow O, Lind C, et al. Association study of two genetic variants in mitochondrial transcription factor a (TFAM) in Alzheimer's and Parkinson's disease. *Neurosci Lett.* 2007;420(3):257-62.
48. Zhu XC, Cao L, Tan MS, Jiang T, Wang HF, Lu H, et al. Association of Parkinson's disease GWAS-linked loci with Alzheimer's disease in Han Chinese. *Mol Neurobiol.* 2017;54(1):308-18.
49. Dermaut B, Singh SK, Engelborghs S, Theuns J, Rademakers R, Saerens J, et al. A novel presenilin 1 mutation associated with Pick's disease but not beta-amyloid plaques. *Ann Neurol.* 2004;55(5):617-26.
50. Cooper CA, Jain N, Gallagher MD, Weintraub D, Xie SX, Berlyand Y, et al. Common variant rs356182 near SNCA defines a Parkinson's disease endophenotype. *Ann Clin Transl Neurol.* 2016;4(1):15-25.
51. Karimi-Moghadam A, Charsouei S, Bell B, Jabalameli MR. Parkinson disease from Mendelian forms to genetic susceptibility: new molecular insights into the neurodegeneration process. *Cell Mol Neurobiol.* 2018;38(6):1153-78.
52. Campelo C, Silva RH. Genetic variants in SNCA and the risk of sporadic Parkinson's disease and clinical outcomes: a review. *Parkinsons Dis.* 2017;2017:4318416.
53. Maple-Groderm J, Chung J, Lunde KA, Tzoulis C, Tysnes OB, Pedersen KF, et al. Alzheimer disease associated variants in SORL1 accelerate dementia development in Parkinson disease. *Neurosci Lett.* 2018;674:123-6.
54. Diner I, Hales CM, Bishof I, Rabenold L, Duong DM, Yi H, et al. Aggregation properties of the small nuclear ribonucleoprotein U1-70K in Alzheimer disease. *J Biol Chem.* 2014;289(51):35296-313.
55. Santiago JA, Potashkin JA. Blood Transcriptomic Meta-analysis Identifies Dysregulation of Hemoglobin and Iron Metabolism in Parkinson' Disease. *Front Aging Neurosci.* 2017;9:73.
56. Bell RD, Sagare AP, Friedman AE, Bedi GS, Holtzman DM, Deane R, et al. Transport pathways for clearance of human Alzheimer's amyloid beta-peptide and apolipoproteins E and J in the mouse central nervous system. *J Cereb Blood Flow Metab.* 2007;27(5):909-18.
57. Deane R, Sagare A, Hamm K, Parisi M, Lane S, Finn MB, et al. ApoE isoform-specific disruption of amyloid beta peptide clearance from mouse brain. *J Clin Invest.* 2008;118(12):4002-13.
58. Miners JS, Baig S, Palmer J, Palmer LE, Kehoe PG, Love S, et al. Abeta-degrading enzymes in Alzheimer's disease. *Brain Pathol.* 2008;18(2):240-52.
59. Macours N, Poels J, Hens K, Francis C, Huybrechts R. Structure, evolutionary conservation, and functions of angiotensin- and endothelinconverting enzymes. *Int Rev Cytol.* 2004;239:47-97.
60. Polymeropoulos MH, Lavedan C, Leroy E, Ide SE, Dehejia A, Dutra A, et al. Mutation in the alpha-synuclein gene identified in families with Parkinson's disease. *Science.* 1997;276(5321):2045-7.
61. Axelsena TM, Woldbye DPD. Gene Therapy for Parkinson's disease, An Update. *J Parkinsons Dis.* 2018;8(2)195-215.
62. Jiang J, Zhu Q, Gendron Tania F, Saberi S, McAlonis-Downes M, Seelman A, et al. Gain of toxicity from ALS/FTD-linked repeat expansions in C9ORF72 is alleviated by antisense oligonucleotides targeting GGG GCC containing RNAs. *Neuron.* 2016;90(3):535-50.
63. DeVos SL, Miller RL, Schoch KM, Holmes BB, Kebodeaux CS, Wegener AJ, et al. Tau reduction prevents neuronal loss and reverses pathological tau deposition and seeding in mice with tauopathy. *Sci Transl Med.* 2017;9(374):eaag0481.
64. Mueller-Steiner S, Zhou Y, Arai H, Roberson ED, Sun B, Chen J, et al. Anti-amyloidogenic and neuroprotective functions of cathepsin B: implications for Alzheimer's disease. *Neuron.* 2006;51(6):703-14.
65. Miller BC, Eckman EA, Sambamurti K, Dobbs N, Chow KM, Eckman CB, et al. Amyloid-beta peptide levels in brain are inversely correlated with insulin activity levels in vivo. *Proc Natl Acad Sci U S A.* 2003;100(10):6221-6.

66. Farris W, Mansourian S, Chang Y, Lindsley L, Eckman EA, Frosch MP, et al. Insulin-degrading enzyme regulates the levels of insulin, amyloid beta-protein, and the beta-amyloid precursor protein intracellular domain in vivo. *Proc Natl Acad Sci U S A*. 2003;100(7):4162-7.
67. Boado R. Blood-brain barrier transport of non-viral gene and RNAi therapeutics. *Pharm Res*. 2007;24(9):1772-87.
68. Zheng H, Jiang M, Trumbauer ME, Sirinathsinghji DJ, Hopkins R, Smith DW, et al. Beta-amyloid precursor protein-deficient mice show reactive gliosis and decreased locomotor activity. *Cell*. 1995;81(4):525-31.
69. Arrant AE, Onyilo VC, Unger DE, Roberson ED. Progranulin gene therapy improves lysosomal dysfunction and microglial pathology associated with frontotemporal dementia and neuronal ceroid lipofuscinosis. *J Neurosci*. 2018;38(9):2341-58.
70. Amado DA, Rieders JM, Diatta F, Hernandez-Con P, Singer A, Mak JT, et al. AAV-mediated progranulin delivery to a mouse model of progranulin deficiency causes T cell-mediated toxicity. *Mol Ther*. 2019;27(2):465-78.
71. Thompson LM. Neurodegeneration: a question of balance. *Nature*. 2008;452(7188):707-8.
72. Mucke L. Neuroscience: Alzheimer's disease. *Nature*. 2009;461(7266):895-7.
73. Daubner SC, Le T, Wang S. Tyrosine hydroxylase and regulation of dopamine synthesis. *Arch Biochem Biophys*. 2011;508(1):1-12.
74. German CL, Baladi MG, McFadden LM, Hanson GR, Fleckenstein AE. Regulation of the Dopamine and Vesicular Monoamine Transporters: Pharmacological Targets and Implications for Disease. *Pharmacol Rev*. 2015;67(4):1005-24.
75. Tang J, Xu H, Fan X, Li D, Rancourt D, Zhou G, et al. Embryonic stem cell derived neural precursor cells improve memory dysfunction in A β (1-40) injured rats. *Neurosci Res*. 2008;62(2):86-96.
76. Li Z, Gao C, Huang H, Sun W, Yi H, Fan X, et al. Neurotransmitter phenotype differentiation and synapse formation of neural precursors engrafting in amyloid- β (1-40) injured rat hippocampus. *J Alzheimers Dis*. 2010;21(4):1233-47.
77. Steinbeck JA, Koch P, Derouiche A, Brüstle O. Human embryonic stem cell-derived neurons establish region-specific, long-range projections in the adult brain. *Cell Mol Life Sci*. 2012;69(3):461-70.
78. Blurton-Jones M, Kitazawa M, Martinez-Coria H, Castello NA, Müller FJ, Loring JF, et al. Neural stem cells improve cognition via BDNF in a transgenic model of Alzheimer disease. *Proc Natl Acad Sci U S A*. 2009;106(32):13594-9.
79. Lue LF, Guerra A, Walker DG. Amyloid Beta and Tau as Alzheimer's disease Blood Biomarkers: Promise from New Technologies. *Neurol Ther*. 2017;6(Suppl 1):25-36.
80. Chojdak-Lukasiewicz J, Małodobra-Mazur M, Zimny A, Noga L, Paradowski B. Plasma tau protein and A β 42 level as markers of cognitive impairment in patients with Parkinson's disease. *Adv Clin Exp Med*. 2020;29(1):115-21.
81. Kanehisa M, Goto S. KEGG: Kyoto encyclopedia of genes and genomes. *Nucleic Acids Res*. 2000;28(1):27-30.
82. Wang Q, Lia WX, Dai SX, Guo YC, Han FF, Zheng JJ, et al. Meta-Analysis of Parkinson's Disease and Alzheimer's Disease Revealed Commonly Impaired Pathways and Dysregulation of NRF2-Dependent Genes. *J Alzheimers Dis*. 2017;56(4):1525-39.
83. Boller F, Mizutani T, Roessmann U, Gambetti P. Parkinson disease, dementia, and Alzheimer disease: Clinicopathological correlations. *Ann Neurol*. 1980;7(4):329-35.
84. Ross CA, Poirier MA. Protein aggregation and neurodegenerative disease. *Nat Med*. 2004;10(Suppl):S10-7.
85. Steffan JS, Bodai L, Pallos J, Poelman M, McCampbell A, Apostol BL, et al. Histone deacetylase inhibitors arrest polyglutamine-dependent neurodegeneration in *Drosophila*. *Nature*. 2001;413(6857):739-43.
86. Ferrante RJ, Kubilus JK, Lee J, Ryu H, Beesen A, Zucker B, et al. Histone deacetylase inhibition by sodium butyrate chemotherapy ameliorates the neurodegenerative phenotype in Huntington's disease mice. *J Neurosci*. 2003;23(28):9418-27.
87. Chen W, Dong G, Wu Y, Zhang W, Miao C, Sheng C. Dual NAMPT/HDAC inhibitors as a new strategy for multitargeting antitumor drug discovery. *ACS Med Chem Lett*. 2017;9(1):34-8.
88. Bustos FJ, Ampuero E, Jury N, Aguilar R, Falahi F, Toledo J, et al. Epigenetic editing of the Dlg4/PSD95 gene improves cognition in aged and Alzheimer's disease mice. *Brain*. 2017;140(12):3252-68.
89. Kacher R, Lamazière A, Heck N, Kappes V, Mounier C, Despres G, et al. CYP46A1 gene therapy deciphers the role of brain cholesterol metabolism in Huntington's disease. *Brain*. 2019;142(8):2432-50.
90. Scervo A, Bourdenx M, Pampliega O, Cuervo AM. Selective autophagy as a potential therapeutic target for neurodegenerative disorders. *Lancet Neurol*. 2018;17(9):802-15.
91. Xiang HG, Zhang JF, Lin CC, Zhang L, Liu B, Ouyang L. Targeting autophagy-related protein kinases for potential therapeutic purpose. *Acta Pharm Sin B*. 2020;10(4):569-81.
92. Du F, Yu Q, Yan S, Hu G, Lue LF, Walker DG, et al. PINK1 signaling rescues amyloid pathology and mitochondrial dysfunction in Alzheimer's disease. *Brain*. 2017;140(12):3233-51.
93. Xilouri M, Brekk OR, Landeck N, Pitychoutis PM, Papisilekas T, Papadopoulou-Daifoti Z. Boosting chaperone-mediated autophagy in vivo mitigates α -synuclein-induced neurodegeneration. *Brain*. 2013;136(Pt 7):2130-46.
94. Decressac M, Mattsson B, Weikop P, Lundblad M, Jakobsson J, Björklund A. TFEB-mediated autophagy rescues midbrain dopamine neurons from α -synuclein toxicity. *Proc Natl Acad Sci U S A*. 2013;110(19):E1817-26.
95. Filézac de L'Etang A, Maharjan N, Cordeiro Braña M, Rueggsegger C, Rehmann R, Goswami A, et al. Marinesco-Sjögren syndrome protein SIL1 regulates motor neuron subtype-selective ER stress in ALS. *Nat Neurosci*. 2015;18(2):227-38.
96. Ian PM, Tang YL. Genetic modification of stem cells for transplantation. *Adv Drug Deliv Rev*. 2008;60(2):160-72.
97. Fisher LJ, Raymon HK, Gage FH. Cells engineered to produce acetylcholine: therapeutic potential for Alzheimer's disease. *Ann N Y Acad Sci*. 1993;695:278-84.
98. Iijima-Ando K, Hearn SA, Granger L, Shenton C, Gatt A, Chiang HC, et al. Overexpression of neprilysin reduces Alzheimer amyloid-beta42 (A β 42)-induced neuron loss and intraneuronal A β 42 deposits but causes a reduction in cAMP-responsive element binding protein-mediated transcription, age-dependent axon pathology, and premature death in *Drosophila*. *J Biol Chem*. 2008;283(27):19066-76.
99. Marr RA, Rockenstein E, Mukherjee A, Kindy MS, Hersh LB, Gage FH, et al. Neprilysin gene transfer reduces human amyloid pathology in transgenic mice. *J Neurosci*. 2003;23(6):1992-6.
100. Habisch HJ, Schmid B, von Arnim CA, Ludolph AC, Brenner R, et al. Efficient processing of Alzheimer's disease amyloid-beta peptides by neuroectodermally converted mesenchymal stem cells. *Stem Cells Dev*. 2009;19(5):629-33.
101. Hemming ML, Patterson M, Reske-Nielsen C, Lin L, Isacson O, Selkoe DJ. Reducing amyloid plaque burden via ex vivo gene delivery of an Abeta-degrading protease: a novel therapeutic approach to Alzheimer disease. *PLoS Med*. 2007;4(8):e262.
102. Chakraborty A, Diwan A. Modified neural stem cells: A new regimen for cell therapy of Alzheimer's and Parkinson's disease. *Current Trends in Neurology*. 2021.
103. Chakraborty A, Diwan A. Cell-Cell interaction: A method to upgrade the Neural Cells Function. *J Neurol Neurophysiol*. 2020;11(4):1-3.
104. Chakraborty A, Diwan A. Coculturing NSCs with Melanocyte Increased its Dopamine and Neural Factor Secretion. *Acta Scientific Neurology*. 2021;4(5):70-8.
105. Chakraborty A, Diwan A. Alzheimer and its possible Therapy: A Review. *J Experiment Neurol*. 2020;1(4):115-22.
106. Chakraborty A, Diwan A. Selection of Cells for Parkinson's Disease Cell-Therapy. *Int J Stem Cell Res Ther*. 2019;6:063.
107. Chakraborty A, Diwan A. Dementia in Parkinson's disease: It's Therapeutics. *SOJ Neurol Neurosci*. 2021;1(1):1-4.